Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Horisaki

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of Epidemiology|June 5, 2018
A Dose-Response Meta-analysis of Coffee Consumption and Colorectal Cancer Risk in the Japanese Population: Application of a Cubic-Spline ModelKen Horisaki, Kunihiko Takahashi, Hidemi Ito, et al.
The Journal of Dermatology|September 6, 2025
Prognosis and Toxicity Stratified by Best Tumor Burden Change in Japanese Patients With Advanced Melanoma Treated With First-Line Programmed Cell Death Protein 1 MonotherapyKen Horisaki, Shusuke Yoshikawa, Wataru Omata, et al.
The Journal of Dermatology|March 5, 2025
Comparison of efficacy and adverse events by treatment cycles of nivolumab and ipilimumab in Japanese melanoma patients: A single-center, retrospective studyKen Horisaki, Shusuke Yoshikawa, Wataru Omata, et al.
Cancers|July 29, 2025
The Real-World Efficacy and Side Effects of Different Nivolumab Regimens in Japanese Patients with Advanced Melanoma: A Single-Center Retrospective StudyKen Horisaki, Shusuke Yoshikawa, Wataru Omata, et al.
The Journal of Dermatology|May 23, 2025
Predictors of Dermal Invasion and Sentinel Lymph Node Metastasis in Patients With Extramammary Paget's Disease Without Clinical Lymph Node EnlargementKen Horisaki, Shusuke Yoshikawa, Wataru Omata, et al.
Cureus|November 29, 2024
A Case of Advanced Extramammary Paget's Disease With a High Tumor Mutation Burden That Showed Partial Lymph Node Regression With PembrolizumabKen Horisaki, Tomoki Taki, Shoichiro Mori, et al.
The Journal of Dermatology|May 5, 2026
Melanoma Dissemination Through Bullous Solar Elastosis: Previously Undescribed Pattern of Cancer DisseminationKen Horisaki, Keisuke Goto, Arata Tsutsumida, et al.
The Journal of Dermatology|October 7, 2025
C-Reactive Protein Kinetics as Prognostic Biomarkers in Stage IV-Melanoma Treated With Immune Checkpoint Inhibitors in the Japanese Population: A Single-Center, Retrospective Cohort StudyKen Horisaki, Shusuke Yoshikawa, Wataru Omata, et al.
The Journal of Dermatology|January 7, 2026
Prognostic Significance of the Modified Glasgow Prognostic Score in Patients With Stage IV Melanoma Receiving Immune Checkpoint Inhibitors: A Single-Center Retrospective StudyKen Horisaki, Shusuke Yoshikawa, Wataru Omata, et al.
Melanoma Research|December 4, 2024
Clinical features of vulvar and vaginal malignant melanomas and the effects of immune checkpoint inhibitors in Japanese patients: a single-center, retrospective cohort studyKen Horisaki, Shusuke Yoshikawa, Wataru Omata, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Epidemiology|June 5, 2018
A Dose-Response Meta-analysis of Coffee Consumption and Colorectal Cancer Risk in the Japanese Population: Application of a Cubic-Spline ModelKen Horisaki, Kunihiko Takahashi, Hidemi Ito, et al.
The Journal of Dermatology|September 6, 2025
Prognosis and Toxicity Stratified by Best Tumor Burden Change in Japanese Patients With Advanced Melanoma Treated With First-Line Programmed Cell Death Protein 1 MonotherapyKen Horisaki, Shusuke Yoshikawa, Wataru Omata, et al.
The Journal of Dermatology|March 5, 2025
Comparison of efficacy and adverse events by treatment cycles of nivolumab and ipilimumab in Japanese melanoma patients: A single-center, retrospective studyKen Horisaki, Shusuke Yoshikawa, Wataru Omata, et al.
Cancers|July 29, 2025
The Real-World Efficacy and Side Effects of Different Nivolumab Regimens in Japanese Patients with Advanced Melanoma: A Single-Center Retrospective StudyKen Horisaki, Shusuke Yoshikawa, Wataru Omata, et al.
The Journal of Dermatology|May 23, 2025
Predictors of Dermal Invasion and Sentinel Lymph Node Metastasis in Patients With Extramammary Paget's Disease Without Clinical Lymph Node EnlargementKen Horisaki, Shusuke Yoshikawa, Wataru Omata, et al.
Cureus|November 29, 2024
A Case of Advanced Extramammary Paget's Disease With a High Tumor Mutation Burden That Showed Partial Lymph Node Regression With PembrolizumabKen Horisaki, Tomoki Taki, Shoichiro Mori, et al.
The Journal of Dermatology|May 5, 2026
Melanoma Dissemination Through Bullous Solar Elastosis: Previously Undescribed Pattern of Cancer DisseminationKen Horisaki, Keisuke Goto, Arata Tsutsumida, et al.
The Journal of Dermatology|October 7, 2025
C-Reactive Protein Kinetics as Prognostic Biomarkers in Stage IV-Melanoma Treated With Immune Checkpoint Inhibitors in the Japanese Population: A Single-Center, Retrospective Cohort StudyKen Horisaki, Shusuke Yoshikawa, Wataru Omata, et al.
The Journal of Dermatology|January 7, 2026
Prognostic Significance of the Modified Glasgow Prognostic Score in Patients With Stage IV Melanoma Receiving Immune Checkpoint Inhibitors: A Single-Center Retrospective StudyKen Horisaki, Shusuke Yoshikawa, Wataru Omata, et al.
Melanoma Research|December 4, 2024
Clinical features of vulvar and vaginal malignant melanomas and the effects of immune checkpoint inhibitors in Japanese patients: a single-center, retrospective cohort studyKen Horisaki, Shusuke Yoshikawa, Wataru Omata, et al.
Pageof 2